🎉 M&A multiples are live!
Check it out!

Nkarta Valuation Multiples

Discover revenue and EBITDA valuation multiples for Nkarta and similar public comparables like Galapagos, Benevolent AI, and Pharming.

Nkarta Overview

About Nkarta

Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.


Founded

2015

HQ

United States of America
Employees

157

Website

nkartatx.com

Financials

LTM Revenue n/a

LTM EBITDA -$118M

EV

-$66.5M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Nkarta Financials

Nkarta has a last 12-month revenue of n/a and a last 12-month EBITDA of -$118M.

In the most recent fiscal year, Nkarta achieved revenue of n/a and an EBITDA of -$119M.

Nkarta expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Nkarta valuation multiples based on analyst estimates

Nkarta P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a n/a XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$126M -$119M XXX XXX XXX
EBITDA Margin -Infinity% -Infinity% XXX XXX XXX
Net Profit -$114M -$118M XXX XXX XXX
Net Margin -Infinity% -Infinity% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Nkarta Stock Performance

As of April 15, 2025, Nkarta's stock price is $2.

Nkarta has current market cap of $121M, and EV of -$66.5M.

See Nkarta trading valuation data

Nkarta Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
-$66.5M $121M XXX XXX XXX XXX $-1.53

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Nkarta Valuation Multiples

As of April 15, 2025, Nkarta has market cap of $121M and EV of -$66.5M.

Nkarta's trades at n/a LTM EV/Revenue multiple, and 0.6x LTM EBITDA.

Analysts estimate Nkarta's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Nkarta and 10K+ public comps

Nkarta Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV -$66.5M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA 0.6x XXX XXX XXX
P/E -1.1x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF 0.6x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Nkarta Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Nkarta Valuation Multiples

Nkarta's NTM/LTM revenue growth is n/a

Nkarta's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $0.8M for the same period.

Over next 12 months, Nkarta's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Nkarta's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Nkarta and other 10K+ public comps

Nkarta Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth n/a XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth -5% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee $0.8M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Nkarta Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Vaccines & Immunotherapies comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Nkarta M&A and Investment Activity

Nkarta acquired  XXX companies to date.

Last acquisition by Nkarta was  XXXXXXXX, XXXXX XXXXX XXXXXX . Nkarta acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Nkarta

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Nkarta

When was Nkarta founded? Nkarta was founded in 2015.
Where is Nkarta headquartered? Nkarta is headquartered in United States of America.
How many employees does Nkarta have? As of today, Nkarta has 157 employees.
Who is the CEO of Nkarta? Nkarta's CEO is Mr. Paul J. Hastings.
Is Nkarta publicy listed? Yes, Nkarta is a public company listed on NAS.
What is the stock symbol of Nkarta? Nkarta trades under NKTX ticker.
When did Nkarta go public? Nkarta went public in 2020.
Who are competitors of Nkarta? Similar companies to Nkarta include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Nkarta? Nkarta's current market cap is $121M
What is the current EBITDA of Nkarta? Nkarta's last 12-month EBITDA is -$118M.
What is the current EV/EBITDA multiple of Nkarta? Current EBITDA multiple of Nkarta is 0.6x.
Is Nkarta profitable? Yes, Nkarta is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.